Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic DermatitisFRIENDSWOOD, Texas, June 16, 2025 (GLOBE ...

Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss impr ...

Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024 Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024 EBITDA loss ...

With skin cancer on the rise across the UK, Boots is expanding dermatology training for its in-store pharmacists. Matt Nixson tried out its mole-scanning service ...

As surprising as it may sound, your elbows can be more than just joints—they can actually reflect internal health issues. Dry ...

Having a dog at home could help to prevent eczema in children who are genetically prone to the condition, a study suggests.

Dermarolling uses tiny needles to puncture skin to promote hair growth and skin rejuvenation. Learn how the process works from start to finish here.

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.